The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.
Bone scintigraphy has long been used to assess Paget's disease and investigate the response to therapy. Objective visual assessment is, however, difficult. The aim of this study was to derive, from a bone scintigram, an index which objectively measured the extent and severity of Paget's disease in the entire skeleton. This whole body index would provide a single numerical value which could be used to monitor the response to therapy in both monostotic and polyostotic disease. Comparison with other methods of assessing the condition, such as biochemical markers and pain scores, would also be possible. The whole body index was developed and used to retrospectively analyse 80 bone scintigrams on 40 patients. The majority of patients (36) received treatment with a bisphosphonate between the two scintigrams. Whole body index was compared with serum alkaline phosphatase measured at the same time; a significant correlation was found (before treatment P=0.001, after treatment P<0.001). The change in whole body index and alkaline phosphatase following treatment with various bisphosphonates was also investigated and a significant correlation found (P<0.001). Whilst performing the analysis it was also noted that the increase in uptake of the radiopharmaceutical was significantly greater in the cortical long bones than in the trabecular axial skeleton. This study suggests that a whole body index may be a suitable tool for assessing the response to treatment in Paget's disease.
Griffith
K
K
Department of Medical Physics, Nottingham City Hospital, Nottingham, UK. kgriffit@ncht.trent.nhs.uk
Pearson
D
D
Parker
C
C
Thorpe
S
S
Vincent
R M
RM
Hosking
D J
DJ
D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000469:Alkaline Phosphatase / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000000981:diagnostic imaging* / Q000188:drug therapy; D000077268:Pamidronate; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014915:Whole-Body Counting
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004164:Diphosphonates; D019275:Radiopharmaceuticals; D000469:Alkaline Phosphatase; D000077268:Pamidronate